Biotech & PharmaSix FDA Oncology Decisions Due in 2026 — ADCs, Cell Therapies, and Checkpoint Inhibitors Face Global Catalyst CalendarSalvado•Jun 19, 2026
Pharmaceuticals & BiotechFDA's H2 2026 Drug Decision Cluster Triggers Global Biotech Repricing in ADCs and Cell TherapiesSalvado•Jun 17, 2026
Pharmaceuticals & BiotechVepdegestrant's 5-Month PFS Anchors Cross-Border Oncology Deals as 2026 PDUFA Cluster Reshapes Global Drug ValuationsSalvado•May 17, 2026
Health & ScienceParadigm Health Activates AI Trial Platform for Amgen and AstraZeneca Simultaneously—Concurrent Launch Stacks Operational RiskSalvado•May 1, 2026
HealthVirtual Heart Simulations Reach 2,000 Clinical Cases as U.S. FDA Establishes Global Standard for Digital TrialsSalvado•Mar 21, 2026
biotechnologyProtara's Bladder Cancer Drug Faces 70% Failure Risk in Trial Watched Across Global Oncology MarketsViaNews Editorial Team•Feb 26, 2026
Pharmaceutical RegulationFDA Moves to Ban Compounded GLP-1 Drugs, Ending $400-Per-Month Alternative to $1,300 Brand Weight-Loss MedicationsViaNews Editorial Team•Feb 21, 2026
pharmaceuticalsNovakand-SVF Vaccines merger faces €2-4M monthly regulatory burn in multi-jurisdiction approval raceViaNews Editorial Team•Feb 20, 2026
Health & ScienceCellectis Bets on Off-the-Shelf CAR-T Revolution as $700M Peak Sales Forecast Puts Global Cell Therapy Race in FocusViaNews Editorial Team•Feb 18, 2026
AnalysisMajor Drugmakers Reshape Cancer Treatment Through Billion-Dollar Acquisitions, FDA ApprovalsViaNews Editorial Team•Feb 15, 2026
